ArticleJournal of pain research2025
Low-Dose IL-2 Attenuates Neuropathic Pain via Treg Expansion in Rats.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Regulatory T cells in perioperative neurocognitive disorders: a systematic review with structured narrative synthesis from molecular mechanisms to clinical translation.Frontiers in molecular neuroscience · 2026Pooled it
- Visualized knowledge mapping on the current research trends and emerging areas of neuroimmune modulation in the past two decades.Frontiers in immunology · 2025Pooled it
- Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo.International journal of molecular sciences · 2026Article
- The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.Inflammopharmacology · 2026Review
- Bioactive compounds for neuroinflammation and neuropathic pain management: molecular and cellular mechanisms.Inflammopharmacology · 2026Review
- IL-2: a promising topical treatment for Sjögren's disease-related dry eye disease.Arthritis research & therapy · 2026Article
- Acid-Responsive Zeolitic Imidazolate Framework-8 Core-Shell Nanovesicles Loaded with Interleukin-2 Nanoplatforms Selectively Expand Regulatory T Cells to Reconstruct Immunometabolic Homeostasis in Diabetic Neuropathy.Biomaterials research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuropathic pain (NP) involves complex neuroimmune interactions. Regulatory T cells (Tregs) have been implicated in immune homeostasis, but their role in NP pathogenesis and therapeutic potential remains poorly understood. Aim: This study aimed to investigate the immunomodulatory effects of low-dose interleukin-2 (IL-2) on Treg populations and neuropathic pain behavior in a rat model of chronic constriction injury (CCI). Methods: CCI was induced in Sprague-Dawley rats, followed by daily intraperitoneal administration of low-dose IL-2 (5000 U/day) for three consecutive days, administered either three days prior to or following CCI. Pain behaviors were assessed by measuring mechanical withdrawal threshold and thermal withdrawal latency. Treg and T conventional (Tconv) cell subsets were quantified by flow cytometry in blood, spleen, dorsal root ganglia (DRG), and spinal cord. Functional markers (CD62L, ICOS) and serum IL-10 concentrations were also examined. Results: CCI increased T cell infiltration in the DRG, with limited endogenous Treg expansion. Low-dose IL-2 significantly elevated Treg proportions in blood, spleen, and DRG, without promoting Tconv expansion. In the DRG, IL-2-treated CCI rats showed a marked increase in Treg proportions, peaking at day 3 (20.73 ± 2.83% vs 6.74 ± 0.67% in controls) and remaining significantly elevated through day 21. IL-2 also enhanced Treg expression of ICOS and CD62L and increased serum IL-10 levels. Rats receiving IL-2 treatment demonstrated significant improvements in mechanical pain thresholds (61.53 ± 8.46% reduction) and thermal pain thresholds (52.74 ± 6.73% reduction) relative to controls on day 21. Preventive IL-2 injection (pre-CCI) was less effective than post-CCI administration. Conclusion: Low-dose IL-2 selectively augments functional Tregs and mitigates neuropathic pain through modulation of peripheral and neural immune responses. Further Treg-specific mechanistic validations are required to confirm its potential for translational clinical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.